
INTERNATIONAL BREAST CANCER CONGRESS DUBLIN/SEPT27

RCSI















IBCCDUBLIN.IE

IN PARTNERSHIP

ABS ASSOCIATION OF BREAST SURGERY

ASBrS The American Society of Breast Surgeons

BREAST SURGEONS of Australia & New Zealand

ENDORSED BY

esso THE EUROPEAN SOCIETY OF SURGICAL ONCOLOGY

FÁILTE
WELCOME

We are delighted to invite you to the International Breast Cancer Congress (IBCC 2027), hosted by RCSI, taking place at the Convention Centre Dublin (CCD) from 9-11 September 2027. IBCC 2027 will serve as a premier global forum for advancing breast cancer research, clinical practice, and patient care.

This multidisciplinary meeting will bring together leading oncologists, surgeons, radiologists, pathologists, researchers, and allied health professionals to share the latest evidence-based strategies and innovations. With expert-led sessions, cutting-edge science, and unparalleled networking opportunities, IBCC 2027 offers a unique chance to engage with global leaders, foster collaboration, and translate research into better outcomes for patients worldwide.

The call for abstracts will launch in October and we look forward to submissions for both oral and poster presentation.

Dublin provides the perfect backdrop for this important exchange of knowledge – a city celebrated for its culture, history, and warm hospitality.

We look forward to your participation in what promises to be an outstanding event.

Warm regards,

Professor Michael J. Kerin
President RCSI;
Chair of Surgery at the University of Galway;
Consultant General and Breast Surgeon at Galway University Hospital

Mr Michael Boland
Consultant Breast and Oncoplastic Breast Surgeon,
St Vincent's University Hospital, Dublin

Professor Janice Walshe
UCD Clinical Professor
Consultant Medical Oncologist
Medical Oncology Department
St Vincent's University Hospital, Dublin

WEDNESDAY, 8 SEPTEMBER 2027
RCSI, 118 ST STEPHEN'S GREEN, DUBLIN 2

PRE-MEETING SYMPOSIA



RCSI, 123 ST STEPHEN'S GREEN, DUBLIN 2



RCSI, 26 YORK STREET, DUBLIN 2




LEADING
THE WORLD
TO BETTER
HEALTH

DAY ONE

THURSDAY, 9 SEPTEMBER 2027

All Day	**Registration**, *Foyer, Ground Floor, CCD*
Morning	Pre-Congress Workshops
15.00	**WELCOME ADDRESS** **Modern Breast Cancer Management - Lessons Learned** **Professor Michael J Kerin**, President RCSI
15.15 - 16.15	**SESSION 1 - COMBINED SESSION** **Translational Challenges in Breast Cancer** What gene expression assay and when in early stage breast cancer? Incorporating circulating DNA into early stage breast cancer: Are we there yet? Margin assessment in breast cancer – will we ever know during the operation?
16.15 - 16.45	*Break and visit the exhibition*
16.45 - 17.15	**KEYNOTE LECTURE** **How far have we come? Reviewing progress over the last decade and predicting what's to come in early and metastatic breast cancer**
17.15 - 18.00	**KEYNOTE LECTURE/DEBATE** **AI and Breast Imaging**
18.00	Welcome Reception



DAY TWO

FRIDAY, 10 SEPTEMBER 2027

CONVENTION CENTRE DUBLIN (CCD),
SPENCER DOCK NORTH WALL QUAY DUBLIN 1 D01 T1W6

07.30 - 08.30	Morning Symposia	
08.30 - 10.00	**SESSION 2 - PARALLEL SESSION**	
	Parallel: Breast Pathology Risk Prediction	**Parallel: Early Stage ER+ HER2 Low Breast Cancer**
	Subtype of Triple Negative breast cancer - a more personalised approach to therapy	Neoadjuvant endocrine therapy: gaining momentum at last?
	Multiomics: Future-Proofing	Who should receive adjuvant CDK4/6 inhibitors and or oral SERDS?
		Ovarian function suppression: Predicting who benefits most?
10.00 - 10.30	*Break and visit the exhibition*	

DAY TWO FRIDAY, 10 SEPTEMBER 2027

10.30 - 12.15	**SESSION 3 - PARALLEL SESSION**	
	Parallel: Management of the Axilla	**Parallel: Early Stage TNBC and HER2 Positive Breast Cancer**
10.30 - 10.50	ALND and TAD in the primary surgery setting – What is the evidence?	Predicting IO benefit and what are the practical implications today?
10.50 - 11.10	ALND is necessary after NACT in node positive patients?	Managing residual disease in early TNBC and HER2 positive breast cancer: what are the options?
11.10 - 11.20	Omission of Sentinel Node Biopsy in Early Breast Cancer Yes or No?	Do all TNBC and HER2 positive breast cancer require adjuvant therapy? How do we decide?
11.20 - 12.15		**Debate: Do Anthracycline have a role in early breast cancer today?**
12.15 - 13.15	*Lunch and visit the exhibition*	
13.15 - 14.15	**SESSION 4 - COMBINED SESSION** **Top Papers of 2026 and 2027: An Overview of What is New** Surgical 30 minutes and Medical Oncology 30 minutes	
14.30 - 15.45	**SESSION 5 - PARALLEL SESSION**	
	Parallel: DCIS	**Parallel: Management of HER-2 Low Disease**
	Radiotherapy is no longer the standard of care for DCIS	HER-2 low cancer is a misclassification and has no therapeutic strategy
	Is Surgery required for all DCIS?	Defining HER-2 low disease pathology
	Decision making algorithms for adjuvant therapies DCIS	Drugs sequencing in HER-2 low breast cancer
15.45 - 16.15	*Break and visit the exhibition*	

DAY TWO FRIDAY, 10 SEPTEMBER 2027

16.15 - 18.00

SESSION 6 - PARALLEL SESSION

Parallel: Innovation

All patients being offered a mastectomy should have access to a robotic procedure. Yes or No?

Breast Conserving Surgery for Multifocal Disease Yes or No?

Role of Lymphodema Surgery in Breast Cancer Patients

Parallel: Metastatic Beast Cancer

Circulating tumour DNA and treatment decisions in the metastatic setting

Treatment approaches for TNBC relapses in first year compared to later

Drug sequencing in HER2-positive metastatic breast cancer

Should all patients with metastatic breast cancer undergo somatic gene analysis?







DAY THREE

SATURDAY, 11 SEPTEMBER 2027

07.30 - 08.30	Morning Symposia	
08.30 - 09.30	**SESSION 7 - PLENARY SESSION**	
	(Oral presentations from submitted abstracts)	
09.30 - 10.30	**SESSION 8 - PARALLEL SESSION**	
	Parallel: Update on Surgical Trials	**Parallel: Survivorship**
		Pregnancy after breast cancer
		Adherence to endocrine therapy and clinical implications
		Strategies to improve adherence to endocrine therapy
		Practical management of ovarian function suppression
		Management of endocrine therapy side effects
		Managing IO toxicity

DAY THREE SATURDAY, 11 SEPTEMBER 2027

10.30 - 11.00	*Break and visit the exhibition*
11.00 - 12.45	**SESSION 9 - COMBINED SESSION** **Lobular Breast Cancer Prospectus from the MDT** Radiology Surgery Medical Oncology
12.45 - 13.45	*Lunch and visit the exhibition*
13.45 - 15.30	**SESSION 10 - COMBINED SESSION** **Genetics and High Risk Screening** - AI/Risk Prediction - Update on Prediction Models **Debate 1** Should all patients with breast cancer have routine germline genetic panel testing? **Debate 2** All patients with high risk penetrance genes should be offered Breast Conserving Therapy?
15.30	*Close of Congress*

CURRENT FACULTY

Dr Judy Boughey M.D.,
Professor of Surgery, Surgical Oncologist & Specialist Breast Surgeon, Mayo Institute

Associate Professor Caroline Baker FRACS
Clinical Program Director, Surgical Services;
Director of Breast Surgery St Vincent's Hospital;
Designated Surgeon St Vincent's BreastScreen;
President, BreastSurgANZ

Laura Esserman MD, MBA
Director, UCSF Breast Care Center
Alfred A. de Lorimier Endowed Chair in General Surgery
Professor of Surgery and Radiology, UCSF

Professor Nuala Healy,
Chair and Professor of Radiology, RCSI and Beaumont Hospital

Professor Arnold Hill,
Dean of Medical Programmes, RCSI University of Medicine and Health Sciences
Professor and Chair of Surgery in RCSI, Beaumont; Consultant General/Breast Surgeon, Beaumont Hospital, Dublin

Dr Andreas Karakatsanis,
Breast Surgeon, Department of Surgical Sciences, Uppsala Universitet

Professor Catherine M. Kelly
UCD Clinical Professor;
Consultant Medical Oncologist, Mater Private Hospital, Dublin

Professor Daniel Richard Leff
FRCS MS (Hons) PhD.,
Professor of Breast Surgery, Chair in Surgical Performance and Precision Surgical Sciences, Department of Surgery and Cancer, Imperial College London

Professor Bruce Mann,
Surgical Oncologist and Specialist Breast Surgeon; Professor of Surgery, University of Melbourne

Professor Stuart McIntosh,
Consultant Breast Surgeon, Professor of Surgical Oncolog, Queens University Belfast

Dr Terri McVeigh
Consultant Clinical Geneticist,
Royal Marsden Hospital, London

Dr Ruth O'Regan,
Medical Oncologist, Chair of Medicine, University of Rochester Medical Center (URMC)

Professor Carlo Palmieri,
Consultant Medical Oncologist & Clinical Scientist, Clatterbridge Cancer Centre

Professor Sarah Pinder
Chair of Breast Pathology at Kings College London

Professor Shelley Potter,
Professor of Surgical Oncology, University of Bristol

Dr Priya Rastogi
Associate Professor of Medicine,
University of Pittsburgh

CURRENT FACULTY

Ms Claire Rutherford,
Consultant Oncoplastic Breast Surgeon,
St. Vincent's University Hospital, Dublin

Dr Paul Thiruchelvam,
Consultant Oncoplastic Breast Surgeon,
Imperial College Healthcare

Professor Alastair Thompson,
Surgical Oncologist and Specialist Breast Surgeon; Section Chief, Breast Surgery,
Baylor College of Medicine

Dr Melanie Walker
Consultant Breast Surgeon
Melbourne

Ms Siún Walsh,
Consultant Breast Surgeon, Mater Misericordiae University Hospital, Dublin

Professor Walter Weber,
Medical Oncologist, University of Basel, Switzerland

Dr Anna Weiss M.D.,
Associate Professor of Surgery, Specialist Breast Surgeon, University Rochester Medicine

Professor Lynda Wyld,
Consultant Oncoplastic Breast Surgeon,
Sheffield University

IBCCDUBLIN.IE







UNIVERSITY
OF MEDICINE
AND HEALTH
SCIENCES

RCSI Ollscoil an Leighis agus na hEolaíochtaí Sláinte

www.rcsi.com